Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells

OncoImmunology

Volumn 6, Issue 10, 2017, Pages

  Al Khami, Amir A ^a,b   Zheng, Liqin ^a   Del Valle, Luis ^a   Hossain, Fokhrul ^a   Wyczechowska, Dorota ^a   Zabaleta, Jovanny ^a   Sanchez, Maria D ^a   Dean, Matthew J ^a   Rodriguez, Paulo C ^c   Ochoa, Augusto C ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Tanta University   (Egypt)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

immune suppression; Immunometabolism; lipids; MDSC; tumor microenvironment

Indexed keywords

ARGININE; CD36 ANTIGEN; CD68 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) METHYLARGININE; OLEIC ACID; STAT3 PROTEIN; STAT5 PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY ASSAY; COLON ADENOCARCINOMA; CONTROLLED STUDY; FATTY ACID OXIDATION; FLOW CYTOMETRY; FUNCTIONAL STATUS; GLYCOLYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; LIPID TRANSPORT; LIPIDOMICS; MEMBRANE POLARIZATION AND DEPOLARIZATION; METABOLIC ACTIVATION; MOUSE; MYELOID-DERIVED SUPPRESSOR CELL; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PERITONEAL FLUID; PROTEIN EXPRESSION; RENAL CELL CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WESTERN BLOTTING;

EID: 85026884063     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1344804     Document Type: Article

References (57)

1. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun 2016; 7:12150; PMID:27381735; https://doi.org/10.1038/ncomms12150
2. Macatangay BJ, Landay AL, Rinaldo CR. MDSC: A new player in HIV immunopathogenesis. AIDS 2012; 26:1567-9; PMID:22810370; https://doi.org/10.1097/QAD.0b013e328355e682
3. Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 2006; 176:2085-94; PMID:16455964; https://doi.org/10.4049/jimmunol.176.4.2085
4. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: Expect the unexpected. J Clin Invest 2015; 125:3356-64; PMID:26168215; https://doi.org/10.1172/JCI80005
5. Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: Critical cells driving immune suppression in the tumor microenvironment. Adv Cancer Res 2015; 128:95-139; PMID:26216631; https://doi.org/10.1016/bs.acr.2015.04.002
6. Ugel S, De SF, Mandruzzato S, Bronte V. Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. J Clin Invest 2015; 125:3365-76; PMID:26325033; https://doi.org/10.1172/JCI80006
7. De SF, Bronte V, Ugel S. Tumor-induced myeloid-derived suppressor cells. Microbiol Spectr 2016; 4; PMID:27337449; https://doi.org/10.1128/microbiolspec.MCHD-0016-2015
8. Condamine T, Ramachandran I, Youn JI, Gabrilovich DI. Regulation of tumor metastasis by myeloid-derived suppressor cells. Annu Rev Med 2015; 66:97-110; PMID:25341012; https://doi.org/10.1146/annurev-med-051013-052304
9. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15:2148-57; PMID:19276286; https://doi.org/10.1158/1078-0432.CCR-08-1332
10. Wesolowski R, Markowitz J, Carson WE, III. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013; 1:10; PMID:24829747; https://doi.org/10.1186/2051-1426-1-10
11. Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 2011; 6:275-97; PMID:21034223; https://doi.org/10.1146/annurev-pathol-011110-130138
12. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, Wagner RA, Greaves DR, Murray PJ, Chawla A. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab 2006; 4:13-24; PMID:16814729; https://doi.org/10.1016/j.cmet.2006.05.011
13. Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, Beatty W, Love-Gregory L, Lam WY, O'Neill CM, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol 2014; 15:846-55; PMID:25086775; https://doi.org/10.1038/ni.2956
14. Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 2015; 161:1527-38; PMID:26073941; https://doi.org/10.1016/j.cell.2015.05.025
15. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, Corzo A, Cho HI, Celis E, Lennox B, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16:880-6; PMID:20622859; https://doi.org/10.1038/nm.2172
16. Ramakrishnan R, Tyurin VA, Veglia F, Condamine T, Amoscato A, Mohammadyani D, Johnson JJ, Zhang LM, Klein-Seetharaman J, Celis E, et al. Oxidized lipids block antigen cross-presentation by dendritic cells in cancer. J Immunol 2014; 192:2920-31; PMID:24554775; https://doi.org/10.4049/jimmunol.1302801
17. Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, et al. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci Immunol 2016; 1; PMID:28417112; https://doi.org/10.1126/sciimmunol.aaf8943
18. Al-Khami AA, Rodriguez PC, Ochoa AC. Energy metabolic pathways control the fate and function of myeloid immune cells. J Leukoc Biol 2017; PMID:28515225; https://doi.org/10.1189/jlb.1VMR1216-535R
19. Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell 2017; 169:570-86; PMID:28475890; https://doi.org/10.1016/j.cell.2017.04.004
20. Al-Khami AA, Rodriguez PC, Ochoa AC. Metabolic reprogramming of myeloid-derived suppressor cells (MDSC) in cancer. OncoImmunology 2016; 5:e1200771; PMID:27622069; https://doi.org/10.1080/2162402X.2016.1200771
21. Hossain F, Al-Khami AA, Wyczechowska D, Hernandez C, Zheng L, Reiss K, Valle LD, Trillo-Tinoco J, Maj T, Zou W, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 2015; 3:1236-47; PMID:26025381; https://doi.org/10.1158/2326-6066.CIR-15-0036
22. Haverkamp JM, Smith AM, Weinlich R, Dillon CP, Qualls JE, Neale G, Koss B, Kim Y, Bronte V, Herold MJ, et al. Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. Immunity 2014; 41:947-59; PMID:25500368; https://doi.org/10.1016/j.immuni.2014.10.020
23. Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, Ugel S, Sonda N, Bicciato S, Falisi E, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32:790-802; PMID:20605485; https://doi.org/10.1016/j.immuni.2010.05.010
24. Lee J, Walsh MC, Hoehn KL, James DE, Wherry EJ, Choi Y. Regulator of fatty acid metabolism, acetyl coenzyme a carboxylase 1, controls T cell immunity. J Immunol 2014; 192:3190-9; PMID:24567531; https://doi.org/10.4049/jimmunol.1302985
25. Yan D, Yang Q, Shi M, Zhong L, Wu C, Meng T, Yin H, Zhou J. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressorcells by activating the JAK/STAT3 pathway. Eur J Immunol 2013; 43:2943-55; PMID:23897117; https://doi.org/10.1002/eji.201343472
26. Rodriguez PC, Ochoa AC. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunol Rev 2008; 222:180-91; PMID:18364002; https://doi.org/10.1111/j.1600-065X.2008.00608.x
27. Raber PL, Thevenot P, Sierra R, Wyczechowska D, Halle D, Ramirez ME, Ochoa AC, Fletcher M, Velasco C, Wilk A, et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2014; 134:2853-64; PMID:24259296; https://doi.org/10.1002/ijc.28622
28. Poschke I, Kiessling R. On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 2012; 144:250-68; PMID:22858650; https://doi.org/10.1016/j.clim.2012.06.003
29. Freigang S, Ampenberger F, Weiss A, Kanneganti TD, Iwakura Y, Hersberger M, Kopf M. Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1alpha and sterile vascular inflammation in atherosclerosis. Nat Immunol 2013; 14:1045-53; PMID:23995233; https://doi.org/10.1038/ni.2704
30. Michalek RD, Gerriets VA, Jacobs SR, Macintyre AN, MacIver NJ, Mason EF, Sullivan SA, Nichols AG, Rathmell JC. Cutting edge: Distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J Immunol 2011; 186:3299-303; PMID:21317389; https://doi.org/10.4049/jimmunol.1003613
31. Robblee MM, Kim CC, Porter AJ, Valdearcos M, Sandlund KL, Shenoy MK, Volmer R, Iwawaki T, Koliwad SK. Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep 2016; 14:2611-23; PMID:26971994; https://doi.org/10.1016/j.celrep.2016.02.053
32. Hale JS, Otvos B, Sinyuk M, Alvarado AG, Hitomi M, Stoltz K, Wu Q, Flavahan W, Levison B, Johansen ML, et al. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells 2014; 32:1746-58; PMID:24737733; https://doi.org/10.1002/stem.1716
33. Laisupasin P, Thompat W, Sukarayodhin S, Sornprom A, Sudjaroen Y. Comparison of serum lipid profiles between normal controls and breast cancer patients. J Lab Physicians 2013; 5:38-41; PMID:24014967; https://doi.org/10.4103/0974-2727.115934
34. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Dionyssiou-Asteriou A. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 2007; 40:1129-34; PMID:17673194; https://doi.org/10.1016/j.clinbiochem.2007.06.007
35. Fiorenza AM, Branchi A, Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000; 30:141-5; PMID:11196072; https://doi.org/10.1007/s005990070013
36. Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov 2016; 6:852-69; PMID:27246539; https://doi.org/10.1158/2159-8290.CD-15-1177
37. Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS 2011; 25:1497-504; PMID:21633288; https://doi.org/10.1097/QAD.0b013e32834917c6
38. Balaban S, Shearer RF, Lee LS, van Geldermalsen M, Schreuder M, Shtein HC, Cairns R, Thomas KC, Fazakerley DJ, Grewal T, et al. Adipocyte lipolysis links obesity to breast cancer growth: Adipocyte-derived fatty acids drive breast cancer cell proliferation and migration. Cancer Metab 2017; 5:1; PMID:28101337; https://doi.org/10.1186/s40170-016-0163-7
39. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. Adipocytes promote ovarian cancer metastasis and provide energy forrapid tumor growth. Nat Med 2011; 17:1498-503; PMID:22037646; https://doi.org/10.1038/nm.2492
40. Pascual G, Avgustinova A, Mejetta S, Martín M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A, Hueto JA, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 2017; 541:41-5; PMID:27974793; https://doi.org/10.1038/nature20791
41. Zechner R, Zimmermann R, Eichmann TO, Kohlwein SD, Haemmerle G, Lass A, Madeo F. FAT SIGNALS–lipases and lipolysis in lipid metabolism and signaling. Cell Metab 2012; 15:279-91; PMID:22405066; https://doi.org/10.1016/j.cmet.2011.12.018
42. O'Sullivan D, van der Windt GJ, Huang SC, Curtis JD, Chang CH, Buck MD, Qiu J, Smith AM, Lam WY, DiPlato LM, et al. Memory CD8(+) T cells use cell-intrinsic lipolysis to support the metabolic programming necessary for development. Immunity 2014; 41:75-88; PMID:25001241; https://doi.org/10.1016/j.immuni.2014.06.005
43. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011; 1812:1007-22; PMID:21382489; https://doi.org/10.1016/j.bbadis.2011.02.014
44. Chawla A. Control of macrophage activation and function by PPARs. Circ Res 2010; 106:1559-69; PMID:20508200; https://doi.org/10.1161/CIRCRESAHA.110.216523
45. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; https://doi.org/10.1038/nri3175
46. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; https://doi.org/10.1038/nri2506
47. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: Moving forward. Discov Med 2010; 10:52-60; PMID:20670599
48. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, Vonderheide RH. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 2012; 21:822-35; PMID:22698406; https://doi.org/10.1016/j.ccr.2012.04.025
49. Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162:5728-37; PMID:10229805
50. Morales JK, Kmieciak M, Knutson KL, Bear HD, Manjili MH. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2010; 123:39-49; PMID:19898981; https://doi.org/10.1007/s10549-009-0622-8
51. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; https://doi.org/10.1084/jem.20080132
52. Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, Katz SC. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther 2016; 23:188-98; PMID:27199222; https://doi.org/10.1038/cgt.2016.19
53. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, Bogner PN, Farren MR, Lee KP, Liu K, et al. Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013; 123:4464-78; PMID:24091328; https://doi.org/10.1172/JCI68189
54. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, Ochoa AC. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69:1553-60; PMID:19201693; https://doi.org/10.1158/0008-5472.CAN-08-1921
55. Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, Ochoa AC, Cui Y, Del Valle L, Rodriguez PC. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 2014; 41:389-401; PMID:25238096; https://doi.org/10.1016/j.immuni.2014.08.015
56. Maddipati KR, Zhou SL. Stability and analysis of eicosanoids and docosanoids in tissue culture media. Prostaglandins Other Lipid Mediat 2011; 94:59-72; PMID:21236355; https://doi.org/10.1016/j.prostaglandins.2011.01.003
57. Maddipati KR, Romero R, Chaiworapongsa T, Zhou SL, Xu Z, Tarca AL, Kusanovic JP, Munoz H, Honn KV. Eicosanomic profiling reveals dominance of the epoxygenase pathway in human amniotic fluid at term in spontaneous labor. FASEB J 2014; 28:4835-46; PMID:25059230; https://doi.org/10.1096/fj.14-254383